Effective treatment of a mouse model of Sjögren's syndrome with eyedrop administration of anti-CD4 monoclonal antibody

Arthritis and Rheumatism

Volumn 50, Issue 9, 2004, Pages 2903-2910

  Hayashi, Yuki ^a   Ishimaru, Naozumi ^b   Arakaki, Rieko ^b   Tsukumo, Shin Ichi ^a   Fukui, Hitomi ^a   Kishihara, Kenji ^a   Shiota, Hiroshi ^a   Yasutomo, Koji ^a   Hayashi, Yoshio ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; EYE DROPS; FODRIN; OKT 4; SPECTRIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; EYE DISEASE; FEMALE; LACRIMAL FLUID; LACRIMAL GLAND; MONONUCLEAR CELL; MOUSE; NONHUMAN; PARENCHYMA; PHENOTYPE; PRIORITY JOURNAL; SALIVARY GLAND; SJOEGREN SYNDROME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; DRY EYE SYNDROMES; FEMALE; LACRIMAL APPARATUS; LYMPHOCYTE ACTIVATION; MICE; MODELS, ANIMAL; OPHTHALMIC SOLUTIONS; SALIVARY GLANDS; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 4444358229     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20472     Document Type: Article

References (36)

1. Sebzda E, Mariathasan S, Ohteki T, Jones R, Bachmann MF, Ohashi PS. Selection of the T cell repertoire. Annu Rev Immunol 1999;17:829-74.
2. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol 2003;21:139-76.
3. Schwartz RH. T cell anergy. Annu Rev Immunol 2003;21:305-34.
4. Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999;17:221-53.
5. Wakeland EK, Liu K, Graham RR, Behrens TW. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001;15:397-408.
6. Yasutomo K. Pathological lymphocyte activation by defective clearance of self-ligands in systemic lupus erythematosus. Rheumatology (Oxford) 2003;42:214-22.
7. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med 2001;7:899-905.
8. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-50.
9. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 2001;28:313-4.
10. Fox RI, Stern M, Michelson P. Update in Sjogren syndrome. Curr Opin Rheumatol 2000;12:391-8.
11. Gordon TP, Bolstad AI, Rischmueller M, Jonsson R, Waterman SA. Autoantibodies in primary Sjogren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 2001;34:123-32.
12. Haneji N, Nakamura T, Takio K, Yanagi K, Higashiyama H, Saito I, et al. Identification of α-fodrin as a candidate autoantigen in primary Sjogren's syndrome. Science 1997;276:604-7.
13. Saegusa K, Ishimaru N, Yanagi K, Arakaki R, Ogawa K, Saito I, et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest 2002;110:361-9.
14. Saegusa K, Ishimaru N, Yanagi K, Mishima K, Arakaki R, Suda T, et al. Prevention and induction of autoimmune exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjogren's syndrome. J Immunol 2002;169:1050-7.
15. Watanabe T, Tsuchida T, Kanda N, Mori K, Hayashi Y, Tamaki K. Anti-α-fodrin antibodies in Sjogren syndrome and lupus erythematosus. Arch Dermatol 1999;135:535-9.
16. Ohno K, Takahashi T, Maki K, Ueda M, Taguchi O. Successful transfer of localized autoimmunity with positively selected CD4+ cells to scid mice lacking functional B cells. Autoimmunity 1999;29:103-10.
17. Tabbara K, Sharara N. Sjogren's syndrome: pathogenesis. Eur J Ophthalmol 1999;9:1-7.
18. Hayashi Y, Haneji N, Hamano H. Pathogenesis of Sjogren's syndrome-like autoimmune lesions in MRL/lpr mice. Pathol Int 1994;44:559-68.
19. Kohriyama K, Katayama Y. Disproportion of helper T cell subsets in peripheral blood of patients with primary Sjogren's syndrome. Autoimmunity 2000;32:67-72.
20. Zeher M, Szodoray P, Gyimesi E, Szondy Z. Correlation of increased susceptibility to apoptosis of CD4+ T cells with lymphocyte activation and activity of disease in patients with primary Sjogren's syndrome. Arthritis Rheum 1999;42:1673-81.
21. Fox RI, Maruyama T. Pathogenesis and treatment of Sjogren's syndrome. Curr Opin Rheumatol 1997;9:393-9.
22. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000;118:1489-96.
23. Hayashi Y, Kojima A, Hata M, Hirokawa K. A new mutation involving the sublingual gland in NFS/N mice: partially arrested mucous cell differentiation. Am J Pathol 1988;132:187-91.
24. Haneji N, Hamano H, Yanagi K, Hayashi Y. A new animal model for primary Sjogren's syndrome in NFS/sld mutant mice. J Immunol 1994;153:2769-77.
25. White SC, Casarett GW. Induction of experimental autoallergic sialadenitis. J Immunol 1974;112:178-85.
26. Delporte C, O'Connell BC, He X, Lancaster HE, O'Connell AC, Agre P, et al. Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc Natl Acad Sci U S A 1997;94:3268-73.
27. Ghobrial RR, Boublik M, Winn HJ, Auchincloss H Jr. In vivo use of monoclonal antibodies against murine T cell antigens. Clin Immunol Immunopathol 1989;52:486-506.
28. Madrenas J, Chau LA, Smith J, Bluestone JA, Germain RN. The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. J Exp Med 1997;185:219-29.
29. Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003;112:101-8.
30. Saegusa K, Ishimaru N, Yanagi K, Haneji N, Nishino M, Azuma M, et al. Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjogren's syndrome (SS) through up-regulated Th2 response. Clin Exp Immunol 2000;119:354-60.
31. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
32. Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003;171:6323-7.
33. Hayashi Y, Haneji N, Hamano H, Yanagi K. Transfer of Sjogren's syndrome-like autoimmune lesions into SCID mice and prevention of lesions by anti-CD4 and anti-T cell receptor antibody treatment. Eur J Immunol 1994;24:2826-31.
34. Tsubota K, Saito I, Ishimaru N, Hayashi Y. Use of topical cyclosporin A in a primary Sjogren's syndrome mouse model. Invest Ophthalmol Vis Sci 1998;39:1551-9.
35. Tornwall J, Lane TE, Fox RI, Fox HS. T cell attractant chemokine expression initiates lacrimal gland destruction in nonobese diabetic mice. Lab Invest 1999;79:1719-26.
36. Amft N, Bowman SJ. Chemokines and cell trafficking in Sjogren's syndrome. Scand J Immunol 2001;54:62-9.